Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Intangibles (2017 - 2025)

Purple Biotech has reported Intangibles over the past 6 years, most recently at $20.7 million for Q4 2022.

  • Quarterly Intangibles rose 0.99% to $20.7 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $20.7 million through Dec 2022, up 0.99% year-over-year, with the annual reading at $20.7 million for FY2022, 0.99% up from the prior year.
  • Intangibles was $20.7 million for Q4 2022 at Purple Biotech, roughly flat from $20.7 million in the prior quarter.
  • Over five years, Intangibles peaked at $20.7 million in Q1 2022 and troughed at $6.2 million in Q2 2018.
  • The 5-year median for Intangibles is $20.5 million (2020), against an average of $16.5 million.
  • Year-over-year, Intangibles changed 0.0% in 2018 and then soared 231.85% in 2020.
  • A 5-year view of Intangibles shows it stood at $6.2 million in 2018, then changed by 0.0% to $6.2 million in 2019, then soared by 231.85% to $20.5 million in 2020, then changed by 0.0% to $20.5 million in 2021, then increased by 0.99% to $20.7 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Intangibles are $20.7 million (Q4 2022), $20.7 million (Q3 2022), and $20.7 million (Q2 2022).